Bulgaria's National Oncology Congress opened in Sofia on 12 November, bringing together specialists to discuss earlier detection and increasingly targeted treatment. The meeting runs until 14 November at the Grand Hotel Millennium and is organised by the Bulgarian Cancer Scientific Society.
At the opening, society chair Professor Assen Dudov argued that the next major step should be earlier diagnosis, backed by a national commitment to screening. The message shifts attention beyond treating established disease to finding cancer before it causes advanced damage.
Precision also depends on diagnosis
The published programme covers several cancers and treatment approaches, including immunotherapy, targeted medicines and antibody-drug conjugates. Sessions address molecular features that can influence which treatment is appropriate, alongside evidence from routine clinical practice.
This does not mean that every patient benefits from the same new medicine. Treatment decisions depend on cancer type, stage, biomarkers, previous therapy and the individual's condition. A conference presentation is also distinct from a new regulatory approval or a decision that a therapy will be reimbursed in Bulgaria.
The forum links that scientific discussion with practical implementation: how specialists interpret evidence, identify suitable patients and apply treatment standards. Earlier diagnosis and access to the necessary tests are part of the same pathway.
For patients, the congress is a meeting about improving care, not an announcement of a universal cure. Its public-health significance lies in whether advances in testing and treatment can be translated into timely, accessible care, while screening policies reach the people they are intended to protect.
